Clinical stage II non-small cell lung cancer: can we “just give adjuvant therapy”?
Despite over 80% of cII patients meeting indications for adjuvant treatment consideration, less than 60% of eligible patients receive it. Failure is associated with worse survival, particularly in upstaged patients; thus, processes should be put in place to help ensure return to intended oncologic therapy or implement practice patterns incorporating neoadjuvant protocols.
Authors
- Neel P. Chudgar (ORCID: https://orcid.org/0000-0003-4736-025X)
- Isaac Loh (ORCID: https://orcid.org/0000-0002-4032-3942)
- Jorge Humberto Rodríguez-Quintero (ORCID: https://orcid.org/0000-0002-6584-7945)
- Brian Cohen
- Rajika Jindani
- Justin Rosario
- Grace Ha
- Tamar B. Nobel
- Marc Vimolratana
- Brendon M. Stiles
Institutions
- Albert Einstein College of Medicine (US)
- Montefiore Medical Center (US)
Publication Details
- Journal
- Journal of Thoracic Disease
- Published
- 2025-12-01
- DOI
- https://doi.org/10.21037/jtd-2025-669
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00